Company news

Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) news

Every Arrowhead Pharmaceuticals, Inc. press release and news update in one place — announcements, filings coverage, and company updates for investors.

Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) news

Press releases & updates

Arrowhead Pharmaceuticals Announces Interim Topline Clinical Data for the First Dual-Functional RNAi Therapeutic for the Treatment of Mixed Hyperlipidemia

Arrowhead Pharmaceuticals to Participate in Upcoming September 2026 Investor Conferences

Arrowhead Pharmaceuticals Presents Phase 3 SHASTA-3 and SHASTA-4 Data Demonstrating Plozasiran Reduced Acute Pancreatitis Events in Patients with Severe Hypertriglyceridemia

Arrowhead Pharmaceuticals to Present New Clinical Data at the European Society of Cardiology Congress

People Living with Familial Chylomicronaemia Syndrome (FCS) in Germany Have Access to REDEMPLO® (plozasiran) as a New Treatment Option to Reduce Triglycerides

Arrowhead Pharmaceuticals Reports Fiscal 2026 Third Quarter Results

Arrowhead Pharmaceuticals Acquires FDA Priority Review Voucher

Arrowhead Pharmaceuticals Completes Enrollment in Global Phase 3 YOSEMITE Study of Zodasiran for the Treatment of Homozygous Familial Hypercholesterolemia

Arrowhead Pharmaceuticals Reports Topline Results from Phase 3 SHASTA-3 and SHASTA-4 Studies of Plozasiran in Patients with Severe Hypertriglyceridemia

Arrowhead Pharmaceuticals to Webcast Fiscal 2026 Third Quarter Results

Arrowhead Pharmaceuticals Receives Marketing Authorization in the European Union for REDEMPLO to Reduce Triglycerides in Adults with Familial Chylomicronemia Syndrome

Arrowhead Pharmaceuticals Receives Marketing Authorization in the European Union for REDEMPLO® (plozasiran) to Reduce Triglycerides in Adults with Familial Chylomicronemia Syndrome (FCS)

Arrowhead Pharmaceuticals to Host a Webinar on its Cardiometabolic Pipeline as Part I of the 2026 Summer Series of R&D Webinars

Arrowhead Pharmaceuticals to Participate in Upcoming June 2026 Events

Arrowhead Pharmaceuticals Presents New Clinical Data on RNAi-based Obesity and MASH Candidate ARO-INHBE at EASL 2026

Arrowhead Pharmaceuticals Presents New Positive Clinical Cardiometabolic Data at the 94th European Atherosclerosis Society (EAS) Congress

Arrowhead Pharmaceuticals Reports Fiscal 2026 Second Quarter Results

Arrowhead Pharmaceuticals Licenses Clinical MASH Program Targeting PNPLA3 to Madrigal Pharmaceuticals

Arrowhead Pharmaceuticals to Participate in Upcoming May 2026 Events

Arrowhead Pharmaceuticals Receives TGA Approval of REDEMPLO® (plozasiran) in Australia, Expanding Global Access for Patients with Familial Chylomicronemia Syndrome (FCS)

Arrowhead Pharmaceuticals Receives Positive CHMP Opinion Recommending Approval of REDEMPLO to Reduce Triglycerides in Adults with Familial Chylomicronemia Syndrome in Europe

Arrowhead Pharmaceuticals Receives Positive CHMP Opinion Recommending Approval of REDEMPLO® (plozasiran) to Reduce Triglycerides in Adults with Familial Chylomicronemia Syndrome (FCS) in Europe

Arrowhead Pharmaceuticals to Webcast Fiscal 2026 Second Quarter Results

Arrowhead Pharmaceuticals Presents New Long-Term Efficacy and Safety Data for Plozasiran Across a Spectrum of Hypertriglyceridemia at the American College of Cardiology's 75th Annual Scientific Session and Expo

Arrowhead Pharmaceuticals Presents New Long-Term Efficacy and Safety Data for Plozasiran Across a Spectrum of Hypertriglyceridemia at the American College of Cardiology’s 75th Annual Scientific Session and Expo

Arrowhead Pharmaceuticals to Participate in Upcoming March 2026 Events

ARWR: Strong Start for REDEMPLO Commercialization…

Arrowhead Pharmaceuticals Reports Fiscal 2026 First Quarter Results

Ciena Set to Join S&P 500; Arrowhead Pharmaceuticals to Join S&P MidCap 400; ADT and OneSpaWorld Holdings to Join S&P SmallCap 600

Arrowhead Pharmaceuticals Initiates Phase 1/2a Study of ARO-DIMER-PA – the First Dual Functional RNAi Therapeutic for the Treatment of Mixed Hyperlipidemia

Arrowhead Pharmaceuticals to Webcast Fiscal 2026 First Quarter Results

Arrowhead Pharmaceuticals Prices Upsized Offerings of Convertible Senior Notes, Common Stock and Pre-Funded Warrants

Arrowhead Pharmaceuticals Announces NMPA Approval of REDEMPLO® (plozasiran) for Familial Chylomicronemia Syndrome (FCS) in China

Arrowhead Pharmaceuticals Announces Proposed Offerings of Convertible Senior Notes and Common Stock

Arrowhead Pharmaceuticals Announces Interim Clinical Data on RNAi-based Obesity Candidates Showing Weight Loss in Obese Patients with Diabetes and Improved Measures of Body Composition

Arrowhead Pharmaceuticals Announces Health Canada Approval of REDEMPLO™ (plozasiran) to Reduce Triglycerides in Adults with Familial Chylomicronemia Syndrome (FCS)

Arrowhead Pharmaceuticals to Participate in Upcoming January 2026 Events

Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

Arrowhead Pharmaceuticals Initiates Phase 1/2a Study of ARO-MAPT for the Treatment of Alzheimer’s Disease and Other Tauopathies

Arrowhead Pharmaceuticals Receives FDA Breakthrough Therapy Designation for Plozasiran in Severe Hypertriglyceridemia

Arrowhead Pharmaceuticals to Participate in Upcoming December 2025 Conferences

Arrowhead Pharmaceuticals Reports 2025 Fiscal Year-End Results

Arrowhead Pharmaceuticals Earns $200 Million Milestone Payment from Sarepta Therapeutics

ARWR: REDEMPLO® Approved by FDA for the Treatment of FCS…

Arrowhead Pharmaceuticals Announces FDA Approval of REDEMPLO® (plozasiran) to Reduce Triglycerides in Adults with Familial Chylomicronemia Syndrome (FCS)

Arrowhead Pharmaceuticals to Webcast Fiscal 2025 Year-End Results

Arrowhead Pharmaceuticals to Participate in Upcoming November 2025 Conferences

Arrowhead Pharmaceuticals Announces Closing of Global License and Collaboration Agreement with Novartis

Arrowhead Pharmaceuticals Files CTA for Investigational ARO-DIMER-PA – the First Dual Functional RNAi Therapeutic for the Treatment of Mixed Hyperlipidemia

Arrowhead Pharmaceuticals Files Complaint for Declaratory Judgment Against Ionis Pharmaceuticals